| Company Name: |
Alfa Aesar |
| Tel: |
400-6106006 |
| Email: |
saleschina@alfa-asia.com |
5'-O-[(N,N-Diisopropylamino)-(2-cyanoethoxy)phosphinyl]-3'-O-(4,4'-dimethoxytrityl)-thymidine manufacturers
|
| | 5'-O-[(N,N-Diisopropylamino)-(2-cyanoethoxy)phosphinyl]-3'-O-(4,4'-dimethoxytrityl)-thymidine Basic information |
| Product Name: | 5'-O-[(N,N-Diisopropylamino)-(2-cyanoethoxy)phosphinyl]-3'-O-(4,4'-dimethoxytrityl)-thymidine | | Synonyms: | 2'-OMe-rU-CE Phosphoramidite;5'-O-[(DiisopropylaMino)-(2-cyanoethoxy)phosphinyl]-3'-O-(4,4'-diMethoxytrityl)thyMidine, 97%;3'-O-DMT-thymidine 5'-CE phosphoramidite;3'-O-[Bis(4-methoxyphenyl)phenylmethyl]thymidine 5'-[2-cyanoethyl bis(1-methylethyl)phosphoramidite];2'-O-Methyl-5'-O-DMT-Uridine-3'-CE-Phosphoramidite;3'-O-(4,4'-Dimethoxytrityl)-thymidine-5'-cyanoethyl-Phosphoramidite;DMT-dT-5'-CE Reverse Phosphoramidite;Thymidine, 3'-O-[bis(4-methoxyphenyl)phenylmethyl]-, 5'-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite] | | CAS: | 134031-86-0 | | MF: | C40H49N4O8P | | MW: | 744.81 | | EINECS: | | | Product Categories: | RNAi;Phosphoramidite | | Mol File: | 134031-86-0.mol | ![5'-O-[(N,N-Diisopropylamino)-(2-cyanoethoxy)phosphinyl]-3'-O-(4,4'-dimethoxytrityl)-thymidine Structure](/CAS/GIF/134031-86-0.gif) |
| | 5'-O-[(N,N-Diisopropylamino)-(2-cyanoethoxy)phosphinyl]-3'-O-(4,4'-dimethoxytrityl)-thymidine Chemical Properties |
| storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO: Sparingly soluble: 1-10 mg/ml
Ethanol: Sparingly soluble: 1-10 mg/ml | | pka | 9.55±0.10(Predicted) |
| | 5'-O-[(N,N-Diisopropylamino)-(2-cyanoethoxy)phosphinyl]-3'-O-(4,4'-dimethoxytrityl)-thymidine Usage And Synthesis |
| Description | 2'-OMe-U Phosphoramidite can be for incorporation of an (otherwise unmodified) reverse (5' to 3') dT nucleobase within an oligonucleotide. | | Uses | 3’-O-DMTr-thymidine 5’-CE phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005
[2] W. MIACHEL HANSON. Reversible Oligonucleotide Chain Blocking Enables Bead Capture and Amplification of T-Cell Receptor α and β Chain mRNAs[J]. Journal of the American Chemical Society, 2016, 138 35: 11073-11076. DOI: 10.1021/jacs.6b04465 |
| | 5'-O-[(N,N-Diisopropylamino)-(2-cyanoethoxy)phosphinyl]-3'-O-(4,4'-dimethoxytrityl)-thymidine Preparation Products And Raw materials |
|